Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionEverhart Financial Group, Inc.
Latest Disclosed Ownership2,455 shares
Latest Disclosed Value $ 1,096,256
Everhart Financial Group, Inc. reports 9.06% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On April 9, 2026 - Everhart Financial Group, Inc. filed a 13F-HR form disclosing ownership of 2,455 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $1,096,256 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 7, 2026 disclosing 2,251 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 9.06% during the quarter. The current value of the position is $1,096,968 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-09 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,455 204 9.06 1,096 7.45 0.0933
2026-01-07 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,251 163 7.81 1,021 24.85 0.0945
2025-11-04 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,088 207 11.00 818 -2.39 0.0820
2025-08-07 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,881 -328 -14.85 837 -21.78 0.0968
2025-04-16 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,209 553 33.39 1,071 60.66 0.1464
2025-01-30 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,656 -480 -22.47 667 -32.93 0.1373
2024-11-04 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,136 617 40.62 993 39.66 0.2201
2024-07-24 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,519 214 16.40 712 30.46 0.1848
2024-05-13 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,305 138 11.83 546 14.98 0.1588
2024-01-12 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,167 53 4.76 475 22.48 0.1682
2023-10-25 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,114 105 10.41 387 9.01 0.1643
2023-07-13 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,009 84 9.08 355 21.99 0.1469
2023-04-25 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 925 120 14.91 291 25.43 0.1308
2023-02-09 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 805 -338 -29.57 232 -29.91 0.1168
2022-10-12 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,143 77 7.22 331 10.33 0.1832
2022-07-12 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,066 1,066 300 0.1823
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.